RNA-Seq of hamster PDAC cancer (HapT1 cell line) biopsies taken after treatment with either an IgG control or new hamster specific anti-PD-L1 monoclonal antibody.

ABSTRACT: 1. The experiment was performed to assess if the newly discovered Syrian hamster specific anti-PD-L1 antibody could induce a biologically relevant change in transcriptome profile in the tumours. This would confirm that the antibody has functional properties. In the larger picture, the Syrian Hamster model is favored over the mouse model for the development of vaccines and testing of oncolytic viruses/immunotherapies. This is because the model is semi permissive to virus replication compared to the mouse model. We can therefore more reliably assess the efficacy of oncolytic virotherapies, mainly oncolysis and promoter specific transgene expression. Moreover, we wanted to test potential improvements to treatment outcomes when combining oncolytic virotherapy and immune checkpoint blockade. Ho

INSTRUMENT(S): Illumina NovaSeq 6000

ORGANISM(S): Mesocricetus auratus

SUBMITTER:  

PROVIDER: E-MTAB-12297 | biostudies-arrayexpress |

SECONDARY ACCESSION(S): ERP141696

REPOSITORIES: biostudies-arrayexpress